These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1175 related articles for article (PubMed ID: 15948743)
1. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743 [TBL] [Abstract][Full Text] [Related]
2. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480 [TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy. Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621 [TBL] [Abstract][Full Text] [Related]
4. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. Andius P; Holmäng S BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147 [TBL] [Abstract][Full Text] [Related]
5. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252 [TBL] [Abstract][Full Text] [Related]
7. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315 [TBL] [Abstract][Full Text] [Related]
8. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798 [TBL] [Abstract][Full Text] [Related]
9. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. Herr HW J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743 [TBL] [Abstract][Full Text] [Related]
10. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer. Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510 [TBL] [Abstract][Full Text] [Related]
11. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805 [TBL] [Abstract][Full Text] [Related]
12. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906). de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P; J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181 [TBL] [Abstract][Full Text] [Related]
13. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Orsola A; Trias I; Raventós CX; Español I; Cecchini L; Búcar S; Salinas D; Orsola I Eur Urol; 2005 Aug; 48(2):231-8; discussion 238. PubMed ID: 15963635 [TBL] [Abstract][Full Text] [Related]
14. Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma. Kondylis FI; Demirci S; Ladaga L; Kolm P; Schellhammer PF J Urol; 2000 Apr; 163(4):1120-3. PubMed ID: 10737479 [TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Järvinen R; Kaasinen E; Sankila A; Rintala E; Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment. Okamura T; Akita H; Imura M; Kaneko T; Mizuno K; Tozawa K; Kohri K Int J Urol; 2008 Oct; 15(11):976-80. PubMed ID: 18721199 [TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association. Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T; Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609 [TBL] [Abstract][Full Text] [Related]
18. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation. Nieder AM; Simon MA; Kim SS; Manoharan M; Soloway MS Urology; 2006 Apr; 67(4):737-41. PubMed ID: 16618564 [TBL] [Abstract][Full Text] [Related]
19. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder. Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737 [TBL] [Abstract][Full Text] [Related]
20. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]